Table 1: Relative risks of cancers associated with use of oral contraceptives and hormone therapy.
Exposure | Cancer site | Detailed exposure | Risk estimate (95% CI) | Source |
---|---|---|---|---|
Oral contraceptives |
Breast | Ever use | 1.08 (1.00-1.17) | Gierisch et al. 20132 |
Endometrium | Ever use | 0.57 (0.43-0.77) | Gierisch et al. 20132 | |
Ovary | Ever use | 0.73 (0.66-0.81) | Havrilesky et al. 20133 | |
Hormone therapy* | Breast | Ever use | 1.39 (1.12-1.72) | Shah et al. 20055 |
Breast | Current use | 1.66 (1.58-1.75) | Beral 200327 | |
Endometrium | Ever use | 0.78 (0.72-0.86) | Brinton et al. 20146 | |
Endometrium | Current use | 0.75 (0.58-0.97) | Beral et al. 200524 | |
Ovary | Ever use | 1.20 (1.15-1.26) | Beral et al. 20157 | |
Ovary | Current use | 1.41 (1.32-1.50) | Beral et al. 20157 |
Note: CI = confidence interval.
*Continuous estrogen-progestin combined hormone therapy (progestins were included in the therapy for > 25 d/mo).